Oppenheimer Maintains Outperform on Corvus Pharma, Lowers Price Target to $7

Benzinga · 03/20 11:14
Oppenheimer analyst Jeff Jones maintains Corvus Pharma (NASDAQ:CRVS) with a Outperform and lowers the price target from $8 to $7.